PRECISION value & health

PRECISIONadvisors

Virtual ISPOR 2021

May 17-20 2021 #ISPORAnnual

PRESENTATION

The New SMC-Ultra-Orphan Pathway: HTA Best Practice for Very Rare Diseases? | This presentation shares challenges for payers and HTA best practices for evaluating medicines in ultra-orphan indications.

Presenter: Richard Macaulay
When: Prerelease session now available!

POSTERS

Latin America HTA: Brazil and Argentina Report Card | This research evaluates HTA reports by CONITEC (used for Brazil) and IECS (used for Argentina).

Authors: Raquel Fernández Dacosta and Richard Macaulay
When: Monday, May 17, 12:45 PM-3:00 PM EST

Canadian Pricing and Reimbursement: Understanding the Biggest Hurdles in the Payer Landscape | This research aims to evaluate which step (PMPRB/CADTH/pCPA) is the most challenging for new therapies to overcome in the Canadian National Health Technology Assessment.

Author: Richard Macaulay
When: Monday, May 17, 12:45 PM-3:00 PM EST

The "NICEness" of NICE: A Time-Trend Analysis | This research evaluates how recommendations by the National Institute for Health and Care Excellence (NICE) have evolved over time.

Author: Richard Macaulay
When: Monday, May 17, 12:45 PM-3:00 PM EST

Impact of COVID on Health Technology Assessment Bodies | This research evaluates the impact of COVID-19 across several major health technology assessment bodies.

Author: Richard Macaulay
When: Monday, May 17, 12:45 PM-3:00 PM EST

The Second Coming of the NICE Appeal Process? | This research systematically evaluates the NICE technology appraisal appeals.

Authors: David Carr and Richard Macaulay
When: Monday, May 17, 12:45 PM-3:00 PM EST

Innovative Approaches to Cancer Therapy Provision in the COVID Era | This research evaluates the interim treatment recommendations provided by NHS England (NHSE) and the Scottish National Cancer Advisory Medicines Group (NCMAG) to guide oncologists during the pandemic.

Author: Richard Macaulay
When: Tuesday, May 18, 11:30 AM-1:45 PM EST

Is the Cancer Drugs Fund Functioning as Anticipated? | This research evaluates all therapies included in the newly reformed Cancer Drugs Fund (CDF).

Author: Richard Macaulay
When: Tuesday, May 18, 11:30 AM-1:45 PM EST

Global Access Implications of Germany's New GSAV Law for Orphan Drugs | This research evaluates the potential impact of the GSAV law through examining any orphan drug subject to a new benefit assessment, after exceeding the annual €50 million threshold.

Authors: Christina Poschen, Sabina Anwar, Richard Macaulay
When: Wednesday, May 19, 11:30 AM-1:45 PM EST

To learn more about PRECISIONadvisors,
visit **www.precisionadvisors.com**.

PRECISIONadvisors
a precision value & health team